Mark Awad

Dr. Mark Awad, a thoracic medical oncologist from Memorial Sloan Kettering, joins the discussion on treating metastatic non-small cell lung cancer (NSCLC) without actionable mutations. He highlights the significance of next-generation sequencing and PD-L1 levels in treatment decisions. Insights into current options for patients with varying PD-L1 scores are shared, detailing single-agent immunotherapy and chemotherapy combinations. Dr. Awad also delves into second-line treatment options and the evolving landscape of targeted therapies, stressing the need for ongoing clinical trials.